Skip to main content
. Author manuscript; available in PMC: 2019 Apr 29.
Published in final edited form as: N Engl J Med. 2017 Jun 22;376(25):2415–2426. doi: 10.1056/NEJMoa1613493

Figure 2 (facing page). Exploratory Subgroup Analyses of Progression-free Survival and Overall Survival.

Figure 2 (facing page).

Panel A shows the subgroup analysis of progression-free survival involving all the patients who underwent random ization, and Panel B the subgroup analysis of overall survival. PD-L1 denotes programmed death ligand 1. The Eastern Cooperative Oncology Group (ECOG) per formance-status score is assessed on a 5-point scale, with higher numbers indicating greater disability. Panel C shows the analysis of progression-free survival among patients who could be evaluated for tumor-mutation burden and who had a high burden. NR denotes not reached. Panel D shows the analysis of progression-free survival among patients who could be evaluated for tumor-mutation burden and who had a low or medium burden. The data for patients with a low or medium tumor-mutation burden were pooled.